Bnb Plus Corp. (NASDAQ: BNBX)

BNB Plus Corp is a Delaware corporation that operates two distinct business lines. The first line is a digital asset treasury that accumulates and manages Binance Coin to generate yield through staking liquidity provision and other decentralized finance activities. The second line is conducted through its majority owned subsidiary LineaRx which develops and commercializes cell free nucleic acid production systems for the biopharmaceutical and diagnostics markets. The company headquarters are located in Stony Brook New York where it maintains laboratories for DNA and RNA manufacturing. BNB Plus Corp aims to leverage its cryptocurrency treasury to support the growth of its life sciences technology while pursuing additional yield opportunities in the Binance ecosystem.

Revenue is generated primarily from the sale of nucleic acid products and services offered by LineaRx. These products include synthetic DNA templates RNA production enzymes and integrated mRNA manufacturing kits that are sold to biotechnology firms research institutions and diagnostic companies. The company also receives fees for custom manufacturing and licensing of its proprietary LineaDNA LineaRNAP and LineaIVT platforms. In addition BNB Plus Corp expects to earn yield from its digital asset treasury through activities such as staking BNB on the Binance Smart Chain providing liquidity on decentralized exchanges participating in Binance Launch Pool airdrops and collateralizing BNB to obtain stablecoins for non directional DeFi strategies. While the treasury yield is still being built the company anticipates that these activities will contribute to future operating income. Overall the firm derives income from both product sales in the life sciences sector and potential returns on its cryptocurrency holdings.

The company operates through the following segments:

• The Digital Asset Treasury segment focuses on acquiring and managing Binance Coin as a reserve asset to produce yield through various Binance ecosystem and decentralized finance opportunities. Activities include staking BNB to validators to support proof of stake consensus and earn transaction fees and block rewards providing liquidity between BNB and liquid staking derivative tokens to capture swap fees participating in Binance Launch Pool to receive airdrops of new project tokens that are sold for immediate profit and using BNB as collateral to borrow stablecoins for non directional DeFi strategies that generate additional returns. The segment also holds units of the OBNB Osprey BNB Chain Trust which may be sold or redeemed to increase the underlying BNB holdings. Custody of the digital assets is maintained with multiple institutional grade custodians in the United States and abroad to reduce reliance on any single provider.

• The Therapeutic DNA Production Services segment conducts its business through the LineaRx subsidiary which develops and sells cell free nucleic acid production solutions for advanced biotherapeutics and diagnostic applications. The segment offers three core technologies the LineaDNA system that uses a polymerase chain reaction process to produce high fidelity synthetic DNA without living cells the LineaRNAP enzyme a modified T7 RNA polymerase designed to deliver high messenger RNA yields with reduced double stranded RNA contamination and the LineaIVT platform that combines LineaDNA LineaRNAP and a proprietary reaction buffer to streamline messenger RNA production while lowering impurities. Products are manufactured at the companys facility in Stony Brook New York under good laboratory and good manufacturing practices and are sold directly to customers or through licensing and fee for service arrangements. The segment also pursues research and development to improve the LineaDNA platform and scale output for larger batch sizes.

In the digital asset treasury space BNB Plus Corp positions itself as a focused manager of Binance Coin seeking to generate yield through staking liquidity provision and decentralized finance strategies that are native to the Binance Smart Chain ecosystem. It competes with other crypto asset managers such as The Ether Machine Sharplink Gaming Inc Strategy Inc Solana Company and various decentralized finance protocols that offer similar yield products. The companys advantage lies in its exclusive dedication to BNB its access to institutional grade custodians and its ability to leverage the OBNB Trust Units for additional exposure. In the nucleic acid production market the company faces established players including MilliporeSigma Precigen Inc Aldevron LLC Integrated DNA Technologies Inc 4basebio PLC MaxCyte Inc Touchlight Genetics Ltd Quantoom Bioscience Syngoi Technologies S L U Novartis AG OriGene Technologies Inc Blue Heron Biotech LLC Gene Art GenScript Biotech Corporation Elegen Inc ANSA Biotechnologies Merck & Co Inc and others. BNB Plus Corp differentiates itself through its cell free manufacturing approach which eliminates the need for bacterial cell culture reduces purification steps and shortens production timelines. Its proprietary LineaRNAP enzyme offers higher messenger RNA yields and lower impurity levels compared to standard T7 polymerase and its integrated LineaIVT system further reduces double stranded RNA contamination while maintaining comparable or improved output.

The company serves a diverse set of customers primarily in the life sciences and cryptocurrency sectors. For its Therapeutic DNA Production Services segment customers include biotechnology firms engaged in gene therapy messenger RNA vaccine development adoptive cell therapy and DNA vaccine research as well as diagnostic companies that require high quality nucleic acids for in vitro testing. The segment also works with contract development and manufacturing organizations that need reliable enzyme supplies for messenger RNA production. In the Digital Asset Treasury segment the counterparties are principally decentralized finance platforms validators liquidity providers and other participants in the Binance Smart Chain ecosystem that facilitate staking swap fee generation and airdrop distributions. While the filing does not disclose the exact names of the major customers it notes that a small number of accounts represent a large portion of revenue and accounts receivable indicating a concentrated customer base.